106 related articles for article (PubMed ID: 36114233)
1. Incidence of and risk factors for severe neutropenia during treatment with the modified FOLFIRINOX therapy in patients with advanced pancreatic cancer.
Irisawa A; Takeno M; Watanabe K; Takahashi H; Mitsunaga S; Ikeda M
Sci Rep; 2022 Sep; 12(1):15574. PubMed ID: 36114233
[TBL] [Abstract][Full Text] [Related]
2. High total bilirubin level is a significant risk factor for severe neutropenia in patients receiving irinotecan-based chemotherapy.
Yamada Y; Fujii H; Ohata K; Kato-Hayashi H; Watanabe D; Ishihara T; Uemura S; Iwashita T; Imai H; Matsuhashi N; Takahashi T; Sugiyama T; Shimizu M; Yoshida K; Suzuki A
Med Oncol; 2019 Jun; 36(7):63. PubMed ID: 31161433
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Prophylactic G-CSF in Patients Receiving FOLFIRINOX: A Preliminary Retrospective Study.
Terazawa T; Goto M; Miyamoto T; Asaishi K; Shimamoto F; Kuwakado S; Nishitani H; Kii T; Higuchi K
Intern Med; 2015; 54(23):2969-73. PubMed ID: 26631878
[TBL] [Abstract][Full Text] [Related]
4. Single-center risk factor analysis for FOLFIRINOX associated febrile neutropenia in patients with pancreatic cancer.
Keum J; Lee HS; Kang H; Jo JH; Chung MJ; Park JY; Park SW; Song SY; Bang S
Cancer Chemother Pharmacol; 2020 Apr; 85(4):651-659. PubMed ID: 32185483
[TBL] [Abstract][Full Text] [Related]
5. The influence of UGT1A1 polymorphisms on modified FOLFIRINOX dose in double-variant-type patients with advanced pancreatic cancer.
Satake T; Morizane C; Maruki Y; Ohba A; Nagashio Y; Kondo S; Hijioka S; Ueno H; Okusaka T
Int J Clin Oncol; 2022 Aug; 27(8):1331-1339. PubMed ID: 35637361
[TBL] [Abstract][Full Text] [Related]
6. Modified FOLFIRINOX versus sequential chemotherapy (FOLFIRI/FOLFOX) as a second-line treatment regimen for unresectable pancreatic cancer: A real-world analysis.
Tezuka S; Ueno M; Oishi R; Nagashima S; Sano Y; Kawano K; Tanaka S; Fukushima T; Asama H; Konno N; Kobayashi S; Morimoto M; Maeda S
Cancer Med; 2022 Feb; 11(4):1088-1098. PubMed ID: 34953056
[TBL] [Abstract][Full Text] [Related]
7. FOLFIRINOX in advanced pancreatic cancer patients with the double-variant type of UGT1A1 *28 and *6 polymorphism: a multicenter, retrospective study.
Umemoto K; Takahashi H; Morizane C; Yamada I; Shimizu S; Shioji K; Yoshida Y; Motoya M; Mizuno N; Kojima Y; Terashima T; Uesugi K; Ueno M; Furuse J; Akimoto T; Ikeda M
Cancer Chemother Pharmacol; 2021 Mar; 87(3):397-404. PubMed ID: 33386925
[TBL] [Abstract][Full Text] [Related]
8. Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older.
Mizrahi JD; Rogers JE; Hess KR; Wolff RA; Varadhachary GR; Javle MM; Shroff RT; Ho L; Fogelman DR; Raghav KPS; Overman MJ; Pant S
Pancreatology; 2020 Apr; 20(3):501-504. PubMed ID: 31932214
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of modified FOLFIRINOX as salvage therapy for patients with refractory advanced biliary tract cancer: a retrospective study.
Ye LF; Ren C; Bai L; Liang JY; Hu MT; Yang H; Wang ZQ; Wang FH; Xu RH; Li YH; Wang DS
Invest New Drugs; 2021 Jun; 39(3):836-845. PubMed ID: 33411209
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer.
Ozaka M; Ishii H; Sato T; Ueno M; Ikeda M; Uesugi K; Sata N; Miyashita K; Mizuno N; Tsuji K; Okusaka T; Furuse J
Cancer Chemother Pharmacol; 2018 Jun; 81(6):1017-1023. PubMed ID: 29633005
[TBL] [Abstract][Full Text] [Related]
11. A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies.
Sharma MR; Joshi SS; Karrison TG; Allen K; Suh G; Marsh R; Kozloff MF; Polite BN; Catenacci DVT; Kindler HL
Cancer; 2019 May; 125(10):1629-1636. PubMed ID: 30645764
[TBL] [Abstract][Full Text] [Related]
12. Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma.
Kim G; Cockrum P; Surinach A; Wang S; Wainberg Z
Curr Med Res Opin; 2022 Aug; 38(8):1295-1303. PubMed ID: 35354375
[TBL] [Abstract][Full Text] [Related]
13. FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer: A subset analysis of data from a nationwide multicenter observational study in Japan.
Kobayashi N; Omae K; Horita Y; Ueno H; Mizuno N; Uesugi K; Sudo K; Ozaka M; Hayashi H; Okano N; Kamei K; Yamaguchi A; Kobayashi S; Suzuki S; Ishihara S; Uchiyama T; Todaka A; Fukutomi A
Pancreatology; 2020 Oct; 20(7):1519-1525. PubMed ID: 32972834
[TBL] [Abstract][Full Text] [Related]
14. A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy.
Hecht JR; Pillai M; Gollard R; Heim W; Swan F; Patel R; Dreiling L; Mo M; Malik I
Clin Colorectal Cancer; 2010 Apr; 9(2):95-101. PubMed ID: 20378503
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of FOLFIRINOX with primary prophylactic pegfilgrastim for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer.
Sasaki M; Ueno H; Mitsunaga S; Ohba A; Hosoi H; Kobayashi S; Ueno M; Terazawa T; Goto M; Inoue D; Namiki S; Sakamoto Y; Kondo S; Morizane C; Ikeda M; Okusaka T
Int J Clin Oncol; 2021 Nov; 26(11):2065-2072. PubMed ID: 34368921
[TBL] [Abstract][Full Text] [Related]
16. Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial.
Alistar A; Morris BB; Desnoyer R; Klepin HD; Hosseinzadeh K; Clark C; Cameron A; Leyendecker J; D'Agostino R; Topaloglu U; Boteju LW; Boteju AR; Shorr R; Zachar Z; Bingham PM; Ahmed T; Crane S; Shah R; Migliano JJ; Pardee TS; Miller L; Hawkins G; Jin G; Zhang W; Pasche B
Lancet Oncol; 2017 Jun; 18(6):770-778. PubMed ID: 28495639
[TBL] [Abstract][Full Text] [Related]
17. Impact of UGT1A1 genetic polymorphism on toxicity in unresectable pancreatic cancer patients undergoing FOLFIRINOX.
Shirasu H; Todaka A; Omae K; Fujii H; Mizuno N; Ozaka M; Ueno H; Kobayashi S; Uesugi K; Kobayashi N; Hayashi H; Sudo K; Okano N; Horita Y; Kamei K; Yukisawa S; Kobayashi M; Fukutomi A
Cancer Sci; 2019 Feb; 110(2):707-716. PubMed ID: 30447099
[TBL] [Abstract][Full Text] [Related]
18. Impact of
Keum J; Lee HS; Jo JH; Chung MJ; Park JY; Park SW; Song SY; Bang S
Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267552
[TBL] [Abstract][Full Text] [Related]
19. Clinical and pharmacogenetic determinants of 5-fluorouracyl/leucovorin/irinotecan toxicity: Results of the PETACC-3 trial.
Tejpar S; Yan P; Piessevaux H; Dietrich D; Brauchli P; Klingbiel D; Fiocca R; Delorenzi M; Bosman F; Roth AD
Eur J Cancer; 2018 Aug; 99():66-77. PubMed ID: 29909091
[TBL] [Abstract][Full Text] [Related]
20. Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Cancer Study Group (KCSG).
Park HS; Kang B; Chon HJ; Im HS; Lee CK; Kim I; Kang MJ; Hwang JE; Bae WK; Cheon J; Park JO; Hong JY; Kang JH; Kim JH; Lim SH; Kim JW; Kim JW; Yoo C; Choi HJ
ESMO Open; 2021 Apr; 6(2):100049. PubMed ID: 33578192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
